Crescent Biopharma price to sales ratio CBIO

Market value divided by revenue over the last twelve months, since 2015.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 29.8×; Jul 2022
Peer median: 1.5×

Crescent Biopharma's price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It was last meaningful in Jul 2022, at 29.8×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2022	29.8×	25.3×	55.5×
2021	57.1×	12.2×	84.4×
2020	n/m a value too high to mean anything
2019	n/m a value too high to mean anything
2018	n/m a value too high to mean anything
2017	n/m a value too high to mean anything
2016	8.1×	3.7×	8.6×
2015	5.4×	5.4×	11.0×

Against its peers

Companies in Drug Manufacturers - General nearest Crescent Biopharma's size, closest first, today.

Company	Price to sales ratio
CBIOCrescent Biopharma	n/m
ARVNArvinas	1.5×
PBYIPuma Biotechnology	2.5×
IRWDIronwood Pharmaceuticals	1.5×
ZVRAZevra Therapeutics	4.3×
CRMDCorMedix	1.3×
COLLCollegium Pharmaceutical	0.9×
ABUSArbutus Biopharma	4.6×
NATRNatures Sunshine Products	0.4×
AMPHAmphastar Pharmaceuticals	1.5×
OMEROmeros	n/m
Peer median	1.5×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Crescent Biopharma

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.